April 18, 2017 / 5:18 AM / 3 months ago

BRIEF-Novartis' Cart-T Therapy CTl019 gets FDA breakthrough therapy designation

1 Min Read

April 18 (Reuters) - Novartis Ag

* Novartis car-t cell therapy ctl019 receives FDA breakthrough therapy designation for treatment of adult patients with r/r DLBCL

* Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

* R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation Source text for Eikon: Further company coverage: (Reporting by John Revill)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below